You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEmpagliflozin
Accession NumberDB09038
TypeSmall Molecule
GroupsApproved
DescriptionEmpagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction.
Structure
Thumb
Synonyms
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
External Identifiers
  • BI 10773
  • BI-10773
  • BI10773
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Jardiancetablet, film coated10 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2014-08-01Not applicableUs
Jardiancetablet, film coated25 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2014-08-01Not applicableUs
Jardiancetablet10 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
Jardiancetablet25 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
GlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
SynjardyBoehringer Ingelheim Pharmaceuticals, Inc.
SaltsNot Available
Categories
UNIIHDC1R2M35U
CAS number864070-44-0
WeightAverage: 450.91
Monoisotopic: 450.1445309
Chemical FormulaC23H27ClO7
InChI KeyOBWASQILIWPZMG-QZMOQZSNSA-N
InChI
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationEmpagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
PharmacodynamicsNot Available
Mechanism of actionEmpagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Related Articles
AbsorptionFollowing oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with AUC decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition.
Volume of distribution

73.8 L

Protein bindingPlasma protein binding was found to be 86.2%
Metabolism

In vitro studies suggest that empaglifozin is primarily metabolized by glucuronidation by 5'-diphospho-glucuronosyltransferases UG2B7, UGT1A3, UGT1A8, and UGT1A9. The most abundant metabolites are three glucuronide metabolites: 2-O-, 3-O-, and 6-O-glucuronide. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. It is a substrate for p-glycoprotein (p-gp), however in vitro studies suggest that it is unlikely to cause interactions with drugs that are p-gp substrates.

SubstrateEnzymesProduct
Empagliflozin
empagliflozin 3-O-glucuronideDetails
Route of eliminationAfter oral administration, empaglifozin was 41.2% eliminated in feces and 54.4% eliminated in urine.
Half lifeTerminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.
Clearance

Apparent oral clearance was found to be 10.6 L/h based on population pharmacokinetic analysis.

ToxicityThe most commonly reported adverse effects for empaglifozin were urinary tract infections, female genital mycotic infections, and dyslipidemia. Because empagliflozin causes osmotic diuresis adverse reactions related to volume depletion were also reported (decreased systolic blood pressure, dehydration, hypotension, orthostatic hypotension, hypovolemia, and syncope). Impaired renal function and hypoglycemia were also reported.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedoral
Tabletoral10 mg
Tabletoral25 mg
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral25 mg/1
Tabletoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6303661 No1997-04-242017-04-24Us
US6890898 No1999-02-022019-02-02Us
US7078381 No1999-02-022019-02-02Us
US7407955 No2003-08-122023-08-12Us
US7459428 No1999-02-022019-02-02Us
US7579449 No2005-11-052025-11-05Us
US7713938 No2007-04-152027-04-15Us
US8119648 No2003-08-122023-08-12Us
US8178541 No2003-08-122023-08-12Us
US8551957 No2009-10-192029-10-19Us
US8673927 No2007-05-042027-05-04Us
US8846695 No2010-06-042030-06-04Us
US8883805 No2005-11-262025-11-26Us
US9173859 No2007-05-042027-05-04Us
USUS7579449 No2005-03-152025-03-15Us
USUS7713938 No2006-04-192026-04-19Us
USWO 201416191 No2014-04-032034-04-03Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.111 mg/mLALOGPS
logP1.79ALOGPS
logP1.66ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area108.61 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity113.79 m3·mol-1ChemAxon
Polarizability45.24 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference
  1. Wang XJ, Zhang L, Byrne D, Nummy L, Weber D, Krishnamurthy D, Yee N, Senanayake CH: Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a beta-glycopyranoside. Org Lett. 2014 Aug 15;16(16):4090-3. doi: 10.1021/ol501755h. Epub 2014 Jul 25. Pubmed
General References
  1. Scheen AJ: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015 Jul;54(7):691-708. doi: 10.1007/s40262-015-0264-4. [PubMed:25805666 ]
  2. Gangadharan Komala M, Mather A: Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9. [PubMed:24716752 ]
  3. Lamos EM, Younk LM, Davis SN: Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19. [PubMed:24746173 ]
  4. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014 Oct;16(10):984-93. doi: 10.1111/dom.12307. Epub 2014 May 28. [PubMed:24766495 ]
  5. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014 Jun;37(6):1650-9. doi: 10.2337/dc13-2105. Epub 2014 Apr 10. [PubMed:24722494 ]
  6. Neumiller JJ: Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014. [PubMed:24991224 ]
  7. Bogdanffy MS, Stachlewitz RF, van Tongeren S, Knight B, Sharp DE, Ku W, Hart SE, Blanchard K: Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol. 2014 Nov-Dec;33(6):436-49. doi: 10.1177/1091581814551648. Epub 2014 Sep 26. [PubMed:25260362 ]
  8. Authors unspecified: Empagliflozin (Jardiance) for diabetes. Med Lett Drugs Ther. 2014 Oct 13;56(1453):99-100. [PubMed:25296258 ]
  9. Jahagirdar V, Barnett AH: Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. [PubMed:25301180 ]
External Links
ATC CodesA10BD20A10BD19A10BX12
AHFS Codes
  • 68:20.18
PDB EntriesNot Available
FDA labelDownload (604 KB)
MSDSDownload (99 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Empagliflozin.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Empagliflozin.
AcetohexamideEmpagliflozin may increase the hypoglycemic activities of Acetohexamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Empagliflozin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Empagliflozin.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Empagliflozin.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Empagliflozin.
AmobarbitalAmobarbital may increase the hypotensive activities of Empagliflozin.
AmoxapineAmoxapine may increase the hypoglycemic activities of Empagliflozin.
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Empagliflozin.
AripiprazoleAripiprazole may increase the hypotensive activities of Empagliflozin.
Arsenic trioxideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Empagliflozin.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.
BarbitalBarbital may increase the hypotensive activities of Empagliflozin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Empagliflozin.
BendroflumethiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Bendroflumethiazide.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Empagliflozin.
BetamethasoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Betamethasone.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Empagliflozin.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Empagliflozin.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.
BrexpiprazoleThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Empagliflozin.
BumetanideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Bumetanide.
BumetanideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bumetanide.
BuserelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Buserelin.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Empagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Empagliflozin.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Empagliflozin.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Empagliflozin.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Empagliflozin.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Empagliflozin.
CeritinibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.
ChlorothiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorothiazide.
ChlorothiazideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Chlorothiazide.
ChlorpropamideEmpagliflozin may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorthalidone.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Chlorthalidone.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.
CitalopramCitalopram may increase the hypoglycemic activities of Empagliflozin.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.
ClomipramineClomipramine may increase the hypoglycemic activities of Empagliflozin.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.
ClozapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.
DapoxetineDapoxetine may increase the hypoglycemic activities of Empagliflozin.
DarunavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.
DiazoxideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Empagliflozin.
DienogestThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the hypoglycemic activities of Empagliflozin.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Empagliflozin.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Empagliflozin.
DinutuximabThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.
DisopyramideEmpagliflozin may increase the hypoglycemic activities of Disopyramide.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.
DrospirenoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Drospirenone.
DuloxetineEmpagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Empagliflozin.
EpinephrineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Empagliflozin.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Empagliflozin.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.
EstradiolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etacrynic acid.
Etacrynic acidThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Etacrynic acid.
Ethinyl EstradiolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinyl Estradiol.
Ethynodiol diacetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.
EtonogestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Empagliflozin.
EverolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.
FenfluramineFenfluramine may increase the hypoglycemic activities of Empagliflozin.
FludrocortisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fludrocortisone.
FluoxetineFluoxetine may increase the hypoglycemic activities of Empagliflozin.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Empagliflozin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Empagliflozin.
FosamprenavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Empagliflozin.
FurosemideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Furosemide.
FurosemideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Furosemide.
GlibornurideEmpagliflozin may increase the hypoglycemic activities of Glibornuride.
GliclazideEmpagliflozin may increase the hypoglycemic activities of Gliclazide.
GlimepirideEmpagliflozin may increase the hypoglycemic activities of Glimepiride.
GlipizideEmpagliflozin may increase the hypoglycemic activities of Glipizide.
GliquidoneEmpagliflozin may increase the hypoglycemic activities of Gliquidone.
GlisoxepideEmpagliflozin may increase the hypoglycemic activities of Glisoxepide.
GlyburideEmpagliflozin may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.
HexobarbitalHexobarbital may increase the hypotensive activities of Empagliflozin.
HistrelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Empagliflozin.
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.
HydrochlorothiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrochlorothiazide.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.
IndalpineIndalpine may increase the hypoglycemic activities of Empagliflozin.
IndapamideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indapamide.
IndapamideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Indapamide.
IndinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.
Insulin AspartEmpagliflozin may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirEmpagliflozin may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineEmpagliflozin may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineEmpagliflozin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanEmpagliflozin may increase the hypoglycemic activities of Insulin Human.
Insulin LisproEmpagliflozin may increase the hypoglycemic activities of Insulin Lispro.
Insulin PorkEmpagliflozin may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypoglycemic activities of Empagliflozin.
IproniazidIproniazid may increase the hypoglycemic activities of Empagliflozin.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Empagliflozin.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Empagliflozin.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Empagliflozin.
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Empagliflozin.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.
LanreotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.
LanreotideEmpagliflozin may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Empagliflozin.
LevodopaEmpagliflozin may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Empagliflozin.
LevonorgestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Empagliflozin.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.
LopinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Empagliflozin.
LurasidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Empagliflozin.
MebanazineMebanazine may increase the hypoglycemic activities of Empagliflozin.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.
MecaserminEmpagliflozin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.
MesalazineMesalazine may increase the hypoglycemic activities of Empagliflozin.
MestranolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Mestranol.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Empagliflozin.
MethohexitalMethohexital may increase the hypotensive activities of Empagliflozin.
MethotrimeprazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methyclothiazide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Methyclothiazide.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.
Methylene blueMethylene blue may increase the hypoglycemic activities of Empagliflozin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Empagliflozin.
MethylprednisoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Empagliflozin.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.
MetolazoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Metolazone.
MetolazoneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Metolazone.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Empagliflozin.
MifepristoneEmpagliflozin may increase the hypoglycemic activities of Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Empagliflozin.
MinaprineMinaprine may increase the hypoglycemic activities of Empagliflozin.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.
MoclobemideMoclobemide may increase the hypoglycemic activities of Empagliflozin.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Empagliflozin.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Empagliflozin.
NateglinideEmpagliflozin may increase the hypoglycemic activities of Nateglinide.
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Empagliflozin.
NelfinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Empagliflozin.
NiacinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Empagliflozin.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Empagliflozin.
NicorandilNicorandil may increase the hypotensive activities of Empagliflozin.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Empagliflozin.
NilotinibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Empagliflozin.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.
NorethisteroneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.
OctamoxinOctamoxin may increase the hypoglycemic activities of Empagliflozin.
OctreotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.
OctreotideEmpagliflozin may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Empagliflozin.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.
OxandroloneOxandrolone may increase the hypoglycemic activities of Empagliflozin.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Empagliflozin.
PaliperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.
PargylinePargyline may increase the hypoglycemic activities of Empagliflozin.
ParoxetineParoxetine may increase the hypoglycemic activities of Empagliflozin.
PasireotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.
PasireotideEmpagliflozin may increase the hypoglycemic activities of Pasireotide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Empagliflozin.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Empagliflozin.
PentamidineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pentamidine.
PentamidineEmpagliflozin may increase the hypoglycemic activities of Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Empagliflozin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Empagliflozin.
PhenelzinePhenelzine may increase the hypoglycemic activities of Empagliflozin.
PheniprazinePheniprazine may increase the hypoglycemic activities of Empagliflozin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Empagliflozin.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Empagliflozin.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Empagliflozin.
PiperazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Empagliflozin.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Empagliflozin.
PolythiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Polythiazide.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.
PrednisoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisone.
PrimidonePrimidone may increase the hypotensive activities of Empagliflozin.
ProgesteroneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Empagliflozin.
QuetiapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.
QuinethazoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quinethazone.
QuinineEmpagliflozin may increase the hypoglycemic activities of Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Empagliflozin.
RasagilineRasagiline may increase the hypoglycemic activities of Empagliflozin.
RepaglinideEmpagliflozin may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.
RisperidoneEmpagliflozin may increase the hypotensive activities of Risperidone.
RisperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.
SafrazineSafrazine may increase the hypoglycemic activities of Empagliflozin.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Empagliflozin.
SaquinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.
SecobarbitalSecobarbital may increase the hypotensive activities of Empagliflozin.
SelegilineSelegiline may increase the hypoglycemic activities of Empagliflozin.
SertralineSertraline may increase the hypoglycemic activities of Empagliflozin.
SirolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Empagliflozin.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Empagliflozin.
StanozololStanozolol may increase the hypoglycemic activities of Empagliflozin.
SulfadiazineEmpagliflozin may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleEmpagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleEmpagliflozin may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibEmpagliflozin may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.
TemsirolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.
TestosteroneTestosterone may increase the hypoglycemic activities of Empagliflozin.
ThiamylalThiamylal may increase the hypotensive activities of Empagliflozin.
ThiopentalThiopental may increase the hypotensive activities of Empagliflozin.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Empagliflozin.
TipranavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.
TolazamideEmpagliflozin may increase the hypoglycemic activities of Tolazamide.
TolbutamideEmpagliflozin may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Empagliflozin.
TorasemideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Torasemide.
TorasemideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Empagliflozin.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Empagliflozin.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Empagliflozin.
TrazodoneTrazodone may increase the hypoglycemic activities of Empagliflozin.
TriamcinoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triamcinolone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Empagliflozin.
TrichlormethiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Trichlormethiazide.
TriptorelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.
VilazodoneVilazodone may increase the hypoglycemic activities of Empagliflozin.
VorinostatThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Empagliflozin.
ZimelidineZimelidine may increase the hypoglycemic activities of Empagliflozin.
ZiprasidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistinhibitor
General Function:
Low-affinity glucose:sodium symporter activity
Specific Function:
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A2
Uniprot ID:
P31639
Molecular Weight:
72895.995 Da
References
  1. Vivian EM: Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014. [PubMed:25598831 ]
Comments
comments powered by Disqus
Drug created on March 31, 2015 20:20 / Updated on September 25, 2016 02:17